Design Therapeutics, Inc.
DSGN
Cena:
$ 10.97
-0.04 (-0.36%)
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
DESIGN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
26-11-2025
CARLSBAD, CALIF., NOV. 26, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLIN...
Více zde
DESIGN THERAPEUTICS ANNOUNCES PLANS TO INITIATE PATIENT DOSING OF DT-818 IN MYOTONIC DYSTROPHY TYPE-1 (DM1) IN THE FIRST HALF OF 2026 AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
05-11-2025
OBTAINED EX-US REGULATORY CLEARANCE FOR DT-818, A POTENTIALLY BEST-IN-DISEASE TREATMENT FOR MYOTONIC...
Více zde
DESIGN THERAPEUTICS APPOINTS JUSTIN GOVER TO BOARD OF DIRECTORS
10-09-2025
CARLSBAD, CALIF., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLI...
Více zde
DESIGN THERAPEUTICS HIGHLIGHTS PROGRESS ACROSS LEAD GENETAC® PROGRAMS AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
07-08-2025
EARLY HUMAN PHARMACOKINETICS DATA FOR DT-216P2 DEMONSTRATES FAVORABLE TRANSLATION FROM NON-HUMAN PRI...
Více zde
DESIGN THERAPEUTICS ANNOUNCES START OF FRIEDREICH ATAXIA PATIENT DOSING EX-U.S. IN ITS RESTORE-FA PHASE 1/2 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216P2
04-06-2025
INITIAL DATA FROM THE ONGOING, BLINDED PHASE 1 SINGLE-ASCENDING DOSE TRIAL HAS DEMONSTRATED FAVORABL...
Více zde
DESIGN THERAPEUTICS TO PARTICIPATE IN 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE
28-05-2025
CARLSBAD, CALIF., MAY 28, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLINI...
Více zde
DESIGN THERAPEUTICS TO PARTICIPATE IN 2025 RBC CAPITAL MARKETS HEALTHCARE CONFERENCE
13-05-2025
CARLSBAD, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLINI...
Více zde
DESIGN THERAPEUTICS HIGHLIGHTS MOMENTUM ACROSS LEAD GENETAC® PROGRAMS AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
07-05-2025
PHASE 1 SINGLE ASCENDING DOSE TRIAL OF DT-216P2 FOR FRIEDREICH ATAXIA (FA) PROGRAM ONGOING REPORTED ...
Více zde
DESIGN THERAPEUTICS ANNOUNCES FAVORABLE PHASE 1 DATA FOR DT-168 SUPPORTING ADVANCEMENT INTO PHASE 2 BIOMARKER TRIAL FOR PATIENTS WITH FUCHS ENDOTHELIAL CORNEAL DYSTROPHY
01-05-2025
PHASE 2 BIOMARKER TRIAL IN FECD PATIENTS ANTICIPATED TO BEGIN IN THE SECOND HALF OF 2025 PHASE 2 BIO...
Více zde
DESIGN THERAPEUTICS TO PRESENT PHASE 1 DATA FOR FUCHS ENDOTHELIAL CORNEAL DYSTROPHY PROGRAM AT EYECELERATOR @ PARK CITY 2025
21-04-2025
CARLSBAD, CALIF., APRIL 21, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLI...
Více zde
DESIGN THERAPEUTICS APPOINTS VETERAN INDUSTRY EXECUTIVE CHRIS STORGARD, M.D., AS CHIEF MEDICAL OFFICER
17-04-2025
CARLSBAD, CALIF., APRIL 17, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLI...
Více zde
DESIGN THERAPEUTICS HIGHLIGHTS PROGRESS ACROSS LEAD GENETAC® PROGRAMS AND REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
10-03-2025
INITIATED PHASE 1 SINGLE ASCENDING DOSE TRIAL OF DT-216P2 IN HEALTHY VOLUNTEERS; FRIEDREICH ATAXIA (...
Více zde
DESIGN THERAPEUTICS TO PARTICIPATE IN LEERINK'S GLOBAL HEALTHCARE CONFERENCE
03-03-2025
CARLSBAD, CALIF., MARCH 03, 2025 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLI...
Více zde
DESIGN THERAPEUTICS TO PARTICIPATE IN MULTIPLE UPCOMING INVESTOR CONFERENCES
13-11-2024
CARLSBAD, CALIF., NOV. 13, 2024 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A CLIN...
Více zde
DESIGN THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND REVIEWS NEAR-TERM MILESTONES FOR GENETACTM PORTFOLIO
07-11-2024
FUCHS ENDOTHELIAL CORNEAL DYSTROPHY (FECD) PHASE 1 TRIAL INITIATED WITH DATA EXPECTED IN THE FIRST H...
Více zde
DESIGN THERAPEUTICS ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND REVIEWS NEAR-TERM MILESTONES FOR GENETAC™ PORTFOLIO
05-08-2024
FRIEDREICH ATAXIA (FA) AND FUCHS ENDOTHELIAL CORNEAL DYSTROPHY (FECD) PROGRAMS ON TRACK AND ADVANCIN...
Více zde
DESIGN THERAPEUTICS ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS UPCOMING PROGRAM MILESTONES
08-05-2024
ADVANCING DT-216P2, NEW DRUG PRODUCT FOR FRIEDREICH ATAXIA (FA), TOWARD CLINICAL TRIALS STARTING PHA...
Více zde
DESIGN THERAPEUTICS TO PARTICIPATE IN THE 2024 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
07-05-2024
CARLSBAD, CALIF., MAY 07, 2024 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A BIOTE...
Více zde
DESIGN THERAPEUTICS OUTLINES PROGRESS ACROSS GENETAC™ PLATFORM AND ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
19-03-2024
NEW DRUG PRODUCT FOR FRIEDREICH ATAXIA (FA) DT-216P2 WITH FAVORABLE NONCLINICAL PHARMACOKINETIC AND ...
Více zde
DESIGN THERAPEUTICS TO WEBCAST FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND COMPREHENSIVE PORTFOLIO UPDATE
12-03-2024
CARLSBAD, CALIF., MARCH 12, 2024 (GLOBE NEWSWIRE) -- DESIGN THERAPEUTICS, INC. (NASDAQ: DSGN), A BIO...
Více zde
DESIGN THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PLANS FOR A COMPREHENSIVE PORTFOLIO UPDATE IN EARLY 2024
13-11-2023
SEASONED BIOTECH EXECUTIVE PRATIK SHAH APPOINTED AS CHIEF EXECUTIVE OFFICER TO LEAD COMPANY TURNAROU...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
09-10-2023
NEW YORK , OCT. 9, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
29-09-2023
NEW YORK , SEPT. 29, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
21-09-2023
NEW YORK , SEPT. 21, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
13-09-2023
NEW YORK , SEPT. 13, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
05-09-2023
NEW YORK , SEPT. 5, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
28-08-2023
NEW YORK , AUG. 28, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF DESIGN THERAPEUTICS, INC. - DSGN
18-08-2023
NEW YORK , AUG. 18, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde
DESIGN THERAPEUTICS PROVIDES PIPELINE UPDATE AND REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
14-08-2023
INITIAL DATA FROM PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216 FOR FRIEDREICH ATAXIA SHOWED SIGNI...
Více zde
DESIGN THERAPEUTICS REPORTS INITIAL RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE STUDY OF DT-216 FOR THE TREATMENT OF FRIEDRICH ATAXIA
14-08-2023
DT-216 RESULTED IN A SIGNIFICANT INCREASE IN FXN MRNA LEVELS IN SKELETAL MUSCLE OF FA PATIENTS TREAT...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2026-01-30 00:00:00 | 8-K |  | Stáhnout |
| 2025-11-05 00:00:00 | 8-K | | Stáhnout |
| 2025-11-05 00:00:00 | 10-Q | | Stáhnout |
| 2025-09-10 01:00:00 | 8-K | | Stáhnout |
| 2025-09-10 00:00:00 | 8-K | | Stáhnout |
| 2025-08-07 01:00:00 | 8-K | | Stáhnout |
| 2025-08-07 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-07 00:00:00 | 8-K | | Stáhnout |
| 2025-08-07 00:00:00 | 10-Q | | Stáhnout |
| 2025-06-12 01:00:00 | 8-K | | Stáhnout |
| 2025-06-12 00:00:00 | 8-K | | Stáhnout |
| 2025-05-07 01:00:00 | 8-K | | Stáhnout |
| 2025-05-07 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-07 00:00:00 | 8-K | | Stáhnout |
| 2025-05-07 00:00:00 | 10-Q | | Stáhnout |
| 2025-03-10 00:00:00 | 8-K | | Stáhnout |
| 2025-03-10 00:00:00 | 10-K | | Stáhnout |
| 2025-03-09 23:00:00 | 8-K | | Stáhnout |
| 2025-03-09 23:00:00 | 10-K | | Stáhnout |
| 2025-01-13 00:00:00 | 8-K | | Stáhnout |
| 2025-01-12 23:00:00 | 8-K | | Stáhnout |
| 2024-11-07 00:00:00 | 8-K | | Stáhnout |
| 2024-11-07 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-06 23:00:00 | 8-K | | Stáhnout |
| 2024-11-06 23:00:00 | 10-Q | | Stáhnout |
| 2024-08-05 01:00:00 | 8-K | | Stáhnout |
| 2024-08-05 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-05 00:00:00 | 8-K | | Stáhnout |
| 2024-08-05 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-17 01:00:00 | 8-K | | Stáhnout |
| 2024-06-17 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-08 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-03-19 00:00:00 | 8-K | | Stáhnout |
| 2024-03-19 00:00:00 | 10-K | | Stáhnout |
| 2024-03-18 23:00:00 | 8-K | | Stáhnout |
| 2024-03-18 23:00:00 | 10-K | | Stáhnout |
| 2023-11-13 00:00:00 | 8-K | | Stáhnout |
| 2023-11-13 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-12 23:00:00 | 8-K | | Stáhnout |
| 2023-11-12 23:00:00 | 10-Q | | Stáhnout |
| 2023-08-25 01:00:00 | 8-K | | Stáhnout |
| 2023-08-25 00:00:00 | 8-K | | Stáhnout |
| 2023-08-14 01:00:00 | 8-K | | Stáhnout |
| 2023-08-14 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-14 00:00:00 | 8-K | | Stáhnout |
| 2023-08-14 00:00:00 | 10-Q | | Stáhnout |
| 2023-06-01 01:00:00 | 8-K | | Stáhnout |
| 2023-06-01 00:00:00 | 8-K | | Stáhnout |
| 2023-05-09 01:00:00 | 8-K | | Stáhnout |
| 2023-05-09 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-09 00:00:00 | 8-K | | Stáhnout |
| 2023-05-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-14 00:00:00 | 8-K | | Stáhnout |
| 2023-03-14 00:00:00 | 10-K | | Stáhnout |
| 2023-03-13 23:00:00 | 8-K | | Stáhnout |
| 2023-03-13 23:00:00 | 10-K | | Stáhnout |
| 2022-11-03 00:00:00 | 8-K | | Stáhnout |
| 2022-11-03 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-02 23:00:00 | 8-K | | Stáhnout |
| 2022-11-02 23:00:00 | 10-Q | | Stáhnout |
| 2022-08-08 01:00:00 | 8-K | | Stáhnout |
| 2022-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-08 00:00:00 | 8-K | | Stáhnout |
| 2022-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-16 01:00:00 | 8-K | | Stáhnout |
| 2022-06-16 00:00:00 | 8-K | | Stáhnout |
| 2022-05-09 01:00:00 | 8-K | | Stáhnout |
| 2022-05-09 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-09 00:00:00 | 8-K | | Stáhnout |
| 2022-05-09 00:00:00 | 10-Q | | Stáhnout |
| 2022-03-22 00:00:00 | 8-K | | Stáhnout |
| 2022-03-21 23:00:00 | 8-K | | Stáhnout |
| 2022-03-10 00:00:00 | 8-K | | Stáhnout |
| 2022-03-10 00:00:00 | 10-K | | Stáhnout |
| 2022-03-09 23:00:00 | 8-K | | Stáhnout |
| 2022-03-09 23:00:00 | 10-K | | Stáhnout |
| 2021-11-09 00:00:00 | 8-K | | Stáhnout |
| 2021-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-08 23:00:00 | 8-K | | Stáhnout |
| 2021-11-08 23:00:00 | 10-Q | | Stáhnout |
| 2021-08-20 01:00:00 | 8-K | | Stáhnout |
| 2021-08-20 00:00:00 | 8-K | | Stáhnout |
| 2021-08-09 01:00:00 | 8-K | | Stáhnout |
| 2021-08-09 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-09 00:00:00 | 8-K | | Stáhnout |
| 2021-08-09 00:00:00 | 10-Q | | Stáhnout |
| 2021-08-06 01:00:00 | 8-K | | Stáhnout |
| 2021-08-06 00:00:00 | 8-K | | Stáhnout |
| 2021-06-07 01:00:00 | 8-K | | Stáhnout |
| 2021-06-07 00:00:00 | 8-K | | Stáhnout |
| 2021-05-10 01:00:00 | 8-K | | Stáhnout |
| 2021-05-10 01:00:00 | 10-Q | | Stáhnout |
| 2021-05-10 00:00:00 | 8-K | | Stáhnout |
| 2021-05-10 00:00:00 | 10-Q | | Stáhnout |
| 2021-03-30 01:00:00 | 8-K | | Stáhnout |
| 2021-03-30 00:00:00 | 8-K | | Stáhnout |
